saemmul o il control cushion 02 natural beige- titanium dioxide, octinoxate, zinc oxide, octisalate powder
the saem international co., ltd. - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w) - purpose: sunscreen
saemmul o il control cushion 01 light beige- titanium dioxide, octinoxate, zinc oxide, octisalate powder
the saem international co., ltd. - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w) - purpose: sunscreen
brenzys 50 mgml
samsung bioepis il ltd, israel - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - rheumatoid arthritisbrenzys is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate. brenzys can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. brenzys, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.juvenile idiopathic arthritistreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents wighing at least 62.5 kg who have had an inadequate response to, or who have proved intolerant of, methotrexate. treatment of psoriatic arthritis in adolescents from the age of 12 years weighing at least 62.5 kg who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years weighing at least 62.5 kg who have had an inadequate response to, or who have proved intolerant of conventional therapy.psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. brenzys has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease.axial spondyloarthritisankylosing spondylitis (as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).plaque psoriasistreatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.paediatric plaque psoriasistreatment of chronic severe plaque psoriasis in children and adolescents weighing at least 62.5 kg who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies
fromilid uno 500 mg prolonged-release tablets
nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - prolonged-release tablet - clarithromycin 500 mg - antibacterials for systemic use
fromilid 500 mg film-coated tablets
nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use
mivacron 10 mg solution for injection
alfred gera & sons limited 10 triq il-masgar, qormi qrm3217, malta - solution for injection - mivacurium 2 mg/ml - muscle relaxants
korean ginseng capsules il hwa
tongil singapore private limited - capsules
corsodyl mouthwash
gsk consumer healthcare, israel ltd - chlorhexidine digluconate - solution - chlorhexidine digluconate 0.2 %w/v - chlorhexidine - chlorhexidine - antibacterial solution for the disinfection of the mouth.1. as an aid to maintaining oral hygiene.2. as an aid in the treatment and prevention of gingivitis.3. inhibition of formation of dental plaque.4. for use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush).5. for use in a post- periodontal surgery or treatment regimen to promote gingival healing.
oracort
taro international ltd, israel - triamcinolone acetonide - paste - triamcinolone acetonide 0.1 % - triamcinolone - triamcinolone - indicated for the adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.
oracort e
taro pharmaceutical industries ltd - lidocaine hydrochloride monohydrate; triamcinolone acetonide - paste - lidocaine hydrochloride monohydrate 3 g / 100 g; triamcinolone acetonide 0.1 g / 100 g - triamcinolone - triamcinolone - adjunctive treatment and temporary relief of pain and symptoms associated with oral inflammatory and ulcerative lesions.